Wanhai Xu

5.0k total citations · 2 hit papers
139 papers, 3.5k citations indexed

About

Wanhai Xu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Wanhai Xu has authored 139 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 32 papers in Pulmonary and Respiratory Medicine and 30 papers in Oncology. Recurrent topics in Wanhai Xu's work include Nanoplatforms for cancer theranostics (27 papers), Bladder and Urothelial Cancer Treatments (20 papers) and Peptidase Inhibition and Analysis (15 papers). Wanhai Xu is often cited by papers focused on Nanoplatforms for cancer theranostics (27 papers), Bladder and Urothelial Cancer Treatments (20 papers) and Peptidase Inhibition and Analysis (15 papers). Wanhai Xu collaborates with scholars based in China, United States and New Zealand. Wanhai Xu's co-authors include Da‐Yong Hou, Hao Wang, Keliang Wang, Man‐Di Wang, Dong‐Bing Cheng, Zeng‐Ying Qiao, Hongtao Lu, Hong‐Wei An, Ziqi Wang and Xingjie Hu and has published in prestigious journals such as Journal of the American Chemical Society, Chemical Society Reviews and Advanced Materials.

In The Last Decade

Wanhai Xu

132 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The promising role of tumor-associated macrophages in the treatment of cancer

2024 79 citations Hongbin Wang, Xueying Wang et al. Drug Resistance Updates profile →
In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy

2024 67 citations Da‐Yong Hou, Dong‐Bing Cheng et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wanhai Xu China	35	1.8k	892	735	669	626	139	3.5k
Jian Ni China	33	1.2k 0.7×	883 1.0×	717 1.0×	571 0.9×	565 0.9×	98	3.2k
Hyewon Youn South Korea	30	1.6k 0.9×	1.0k 1.1×	493 0.7×	466 0.7×	365 0.6×	108	3.6k
Jun Qian China	28	1.9k 1.1×	514 0.6×	436 0.6×	577 0.9×	681 1.1×	113	3.5k
Jihong Sun China	30	1.3k 0.7×	1.3k 1.5×	362 0.5×	902 1.3×	432 0.7×	129	3.6k
Kun Cheng United States	36	2.5k 1.4×	684 0.8×	453 0.6×	698 1.0×	265 0.4×	102	4.4k
Andreas Wicki Switzerland	27	1.8k 1.0×	1.0k 1.1×	453 0.6×	1.1k 1.7×	455 0.7×	81	4.6k
In-San Kim South Korea	36	2.1k 1.2×	886 1.0×	520 0.7×	967 1.4×	209 0.3×	68	3.8k
Peter Laverman Netherlands	41	1.6k 0.9×	698 0.8×	381 0.5×	1.1k 1.6×	676 1.1×	123	5.2k
Jiandong Wang China	29	1.3k 0.8×	519 0.6×	670 0.9×	233 0.3×	424 0.7×	139	3.3k
Marcel H.A.M. Fens Netherlands	28	1.7k 1.0×	720 0.8×	583 0.8×	1.0k 1.5×	258 0.4×	69	3.3k

Countries citing papers authored by Wanhai Xu

Since Specialization

Citations

This map shows the geographic impact of Wanhai Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanhai Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanhai Xu more than expected).

Fields of papers citing papers by Wanhai Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanhai Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanhai Xu. The network helps show where Wanhai Xu may publish in the future.

Co-authorship network of co-authors of Wanhai Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Wanhai Xu. A scholar is included among the top collaborators of Wanhai Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanhai Xu. Wanhai Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jia, Fan, Da‐Yong Hou, Han Zhang, et al.. (2025). Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 53(3). 1593–1607.

Tai, Sheng, Ye Wang, Sunyi Ye, et al.. (2025). Safety and reliability of telesurgery in China: a multicenter, single-arm, phase I clinical trial. International Journal of Surgery. 111(10). 6678–6687. 1 indexed citations

Hou, Da‐Yong, et al.. (2025). Intracellular aggregation of exogenous molecules for biomedical applications. Chemical Society Reviews. 54(13). 6412–6447. 5 indexed citations

An, Hong‐Wei, Da‐Yong Hou, Ni‐Yuan Zhang, et al.. (2024). A self-assembled fluorescent contrast agent targeting XIAP for image-guided surgery of bladder cancer. Nano Today. 56. 102313–102313. 8 indexed citations

Wang, Hongbin, Xueying Wang, Xin Zhang, & Wanhai Xu. (2024). The promising role of tumor-associated macrophages in the treatment of cancer. Drug Resistance Updates. 73. 101041–101041. 79 indexed citations breakdown →

Yang, Guang, Xinyue Wang, Yuting Wang, et al.. (2023). Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy. Frontiers in Bioscience-Landmark. 28(12). 334–334. 6 indexed citations

Guo, Pengyu, Peng Dai, Shenghao Yang, et al.. (2023). Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled Self‐Pyroptosis to Enhance Bladder Cancer Immunotherapy. Small. 20(13). e2306699–e2306699. 10 indexed citations

Wang, Changlin, et al.. (2023). Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. Journal of Clinical Medicine. 12(5). 1861–1861. 2 indexed citations

Wang, Lu, et al.. (2023). LncRNA PVT1 promotes strong stemness and endothelial progenitor cell characteristics in renal carcinoma stem cells. The FASEB Journal. 37(9). e23118–e23118. 6 indexed citations

10.

Tang, Bo, Yinhui Yang, Zhaogang Yang, et al.. (2021). MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. Cancer Research. 81(17). 4471–4484. 11 indexed citations

11.

Shi, Lei, Yuqian Yan, Yundong He, et al.. (2021). Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Cancer Research. 81(13). 3593–3606. 25 indexed citations

12.

Wang, Keliang, Jie Luo, Shuyuan Yeh, et al.. (2020). The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nature Communications. 11(1). 2689–2689. 52 indexed citations

13.

Wang, Lu, Cong Li, Guang Yang, et al.. (2020). Transformable Dual‐Inhibition System Effectively Suppresses Renal Cancer Metastasis through Blocking Endothelial Cells and Cancer Stem Cells. Small. 16(40). e2004548–e2004548. 37 indexed citations

14.

Wang, Hui, Wanhai Xu, Yuying Zhao, et al.. (2019). The correlation of ESCO1 expression with a prognosis of prostate cancer and anti-tumor effect of ESCO1 silencing. Translational Cancer Research. 8(3). 950–961. 1 indexed citations

15.

He, Yundong, Yinhui Yang, Zhenqing Ye, et al.. (2018). TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53 -Mutated Prostate Cancer. Clinical Cancer Research. 24(18). 4551–4565. 51 indexed citations

16.

Li, Peng, Wenting Shang, Pengyu Guo, et al.. (2018). Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study. Molecular Cancer Therapeutics. 17(10). 2100–2111. 15 indexed citations

17.

Yan, Hao, Xiaodan Sun, Lingyun Zhao, et al.. (2018). Neoadjuvant nano-photothermal therapy used before operation effectively assists in surgery for breast cancer. Nanoscale. 11(2). 706–716. 15 indexed citations

18.

Yang, Yinhui, Yang Bai, Yundong He, et al.. (2017). PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clinical Cancer Research. 24(4). 834–846. 50 indexed citations

19.

Yang, Yinhui, Dejie Wang, Jian An, et al.. (2017). Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer Research. 77(23). 6524–6537. 47 indexed citations

20.

Ren, Minghua, Cheng Zhang, Weijun Fu, et al.. (2014). Balloon dilation versus Amplatz dilation during ultrasound-guided percutaneous nephrolithotomy for staghorn stones. Chinese Medical Journal. 127(6). 1057–1061. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact